EGFR and neoplasm: Poor-quality tumour DNA precluded assessment of ERBB3 mutation(s) in our family, noting that somatic mutations were not identified in the single family with the germline ERBB2 mutation and NSCLC (23) and inconsistently in individuals and families with EGFR/ERBB1 mutations (59).